{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:39Z","timestamp":1790660739864,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-060164"],"award-info":[{"award-number":["INV-060164"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jconrel.2026.114806","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:23:48Z","timestamp":1773249828000},"page":"114806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of high-concentration long-acting injectable formulations of TBAJ-587 and TBAJ-876 as an extended treatment strategy against tuberculosis"],"prefix":"10.1016","volume":"393","author":[{"given":"Mads Fahn\u00f8e","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadina","family":"Zulbeari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Morgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2026.114806_bb0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40199-018-00235-2","article-title":"Formation of nanosuspensions in bottom-up approach: theories and optimization","volume":"27","author":"Ahmadi Tehrani","year":"2019","journal-title":"Daru"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114806_bb0010","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1021\/acs.molpharmaceut.4c00665","article-title":"Patient-centric long-acting injectable and implantable platformsan industrial perspective","volume":"21","author":"Alidori","year":"2024","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114806_bb0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01412-21","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-876 and Bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Almeida","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3390\/pharmaceutics12030286","article-title":"Development and evaluation of a reconstitutable dry suspension containing isoniazid for flexible pediatric dosing","volume":"12","author":"Adeleke","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114806_bb0025","first-page":"499","article-title":"Is the combination of cellulosic polymers and anionic surfactants a good strategy for ensuring physical stability of BCS class II drug nanosuspensions?","volume":"21","author":"Bilgili","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2026.114806_bb0030","article-title":"The pipeline of new molecules and regimens against drug-resistant tuberculosis","volume":"25","author":"Black","year":"2021","journal-title":"J. Clin. Tuber. Other Mycobacter. Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114806_bb0035","doi-asserted-by":"crossref","first-page":"2000718","DOI":"10.1183\/13993003.00718-2020","article-title":"The looming threat of bedaquiline resistance in tuberculosis","volume":"55","author":"Chiang","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114806_bb0040","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/molecules25061423","article-title":"Synthetic studies to help elucidate the metabolism of the preclinical candidate TBAJ-876-a less toxic and more potent analogue of bedaquiline","volume":"25","author":"Choi","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114806_bb0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijpharm.2010.02.013","article-title":"Understanding the structure and stability of paclitaxel nanocrystals","volume":"390","author":"Deng","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114806_bb0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114806_bb0055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426827122","article-title":"Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity","volume":"122","author":"Fountain","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.114806_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2011.02.051","article-title":"Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth","volume":"409","author":"Ghosh","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114806_bb0065","first-page":"428","article-title":"Development of cyclosporine a nanosuspension using an experimental design based on response surface methodology: in vitro evaluations","volume":"21","author":"G\u00fclba\u011f P\u0131nar","year":"2024","journal-title":"Turk. J. Pharmaceut. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.114806_bb0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejps.2012.10.004","article-title":"Identifying the correlation between drug\/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology","volume":"48","author":"George","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0075","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/0378-5173(92)90184-4","article-title":"The relationship between particle size and solubility","volume":"82","author":"Buckton","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114806_bb0080","doi-asserted-by":"crossref","first-page":"126103","DOI":"10.1016\/j.ijpharm.2025.126103","article-title":"Development of highly concentrated bedaquiline suspensions for usage as long-acting injectable formulations","volume":"684","author":"Hansen","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.114806_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2017.07.047","article-title":"Dual centrifugation - a new technique for nanomilling of poorly soluble drugs and formulation screening by an DoE-approach","volume":"530","author":"Hagedorn","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-023-00811-8","article-title":"Long-acting injectable aqueous suspensions-Summary from an AAPS workshop","volume":"25","author":"Holm","year":"2023","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114806_bb0095","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/pharmaceutics15102493","article-title":"Influence of intermolecular interactions on crystallite size in crystalline solid dispersions","volume":"15","author":"Huang","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.114806_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2005.05.014","article-title":"Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine","volume":"299","author":"Hecq","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejpb.2006.05.008","article-title":"Preparation and in vitro\/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base","volume":"64","author":"Hecq","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114806_bb0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2021.12.011","article-title":"Effect of particle size on in vivo performances of long-acting injectable drug suspension","volume":"341","author":"Ho","year":"2022","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.114806_bb0115","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2010.10.055","article-title":"Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying","volume":"404","author":"Hu","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114806_bb0120","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1208\/s12249-010-9440-x","article-title":"Formulation development of parenteral phospholipid-based microemulsion of etoposide","volume":"11","author":"Jain","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114806_bb0125","series-title":"Pharmaceutical Composition Containing Solid Dispersion of Drug","author":"Kaneko","year":"2013"},{"key":"10.1016\/j.jconrel.2026.114806_bb0130","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/PPA.S53795","article-title":"Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia","volume":"7","author":"Kaplan","year":"2013","journal-title":"Patient Prefer. Adherence"},{"issue":"7","key":"10.1016\/j.jconrel.2026.114806_bb0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.addr.2007.05.003","article-title":"Nanosizing-oral formulation development and biopharmaceutical evaluation","volume":"59","author":"Kesisoglou","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114806_bb0140","doi-asserted-by":"crossref","first-page":"113793","DOI":"10.1016\/j.jconrel.2025.113793","article-title":"Particle size matters: The impact of particle size on properties and performance of long-acting injectable crystalline aqueous suspensions","volume":"383","author":"Liu","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114806_bb0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics16010028","article-title":"Long-acting injectable antipsychotics-a review on formulation and in vitro dissolution","volume":"16","author":"Markowicz-Piasecka","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114806_bb0150","doi-asserted-by":"crossref","first-page":"e1366","DOI":"10.1093\/infdis\/jiae332","article-title":"Relative contributions of the novel diarylquinoline TBAJ-876 and its active metabolite to the bactericidal activity in a murine model of tuberculosis","volume":"230","author":"Mudde","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114806_bb0155","first-page":"1120","article-title":"Pediatric tuberculosis management: a global challenge or breakthrough?","volume":"9","author":"Maphalle","year":"2022","journal-title":"Children (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114806_bb0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/schbul\/sbn067","article-title":"Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia","volume":"35","author":"Mohamed","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0165","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.drudis.2018.01.016","article-title":"Pharmaceutical nanocrystals: production by wet milling and applications","volume":"23","author":"Malamatari","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.114806_bb0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijpharm.2014.09.048","article-title":"Engineering of nano-crystalline drug suspensions: employing a physico-chemistry based stabilizer selection methodology or approach","volume":"476","author":"Nakach","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0175","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/inm.12964","article-title":"The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: a systematic review and meta-analysis","volume":"31","author":"Okoli","year":"2022","journal-title":"Int. J. Ment. Health Nurs."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0180","first-page":"177","article-title":"Global treatment outcomes of extensively drug-resistant tuberculosis in adults: a systematic review and meta-analysis","volume":"87","author":"Pedersen","year":"2023","journal-title":"J. Inf. Secur."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114806_bb0185","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0190","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.00720-11","article-title":"Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis","volume":"56","author":"Rouan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/15748847113089990051","article-title":"The pharmacokinetics of long-acting antipsychotic medications","volume":"9","author":"Spanarello","year":"2014","journal-title":"Curr. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114806_bb0200","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/0004867412470010","article-title":"Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review","volume":"47","author":"Taylor","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2 Pt 2","key":"10.1016\/j.jconrel.2026.114806_bb0205","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.lpm.2017.01.016","article-title":"The challenge of the new tuberculosis drugs","volume":"46","author":"Tiberi","year":"2017","journal-title":"Presse Med. (Paris, France\u202f: 1983)"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114806_bb0210","doi-asserted-by":"crossref","first-page":"e02418","DOI":"10.1128\/AAC.02418-20","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Xu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8020","key":"10.1016\/j.jconrel.2026.114806_bb0215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41586-024-07605-8","article-title":"Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587","volume":"631","author":"Zhang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114806_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124760","article-title":"Temperature mapping of milling by dual centrifugation: a systematic investigation","volume":"666","author":"Zulbeari","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114806_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106980","article-title":"Small-scale aqueous suspension preparation using dual centrifugation: the effect of process parameters on the sizes of drug particles","volume":"205","author":"Zulbeari","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bb0230","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jconrel.2013.08.006","article-title":"Stability of nanosuspensions in drug delivery","volume":"172","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114806_bb0235","author":"WHO"},{"key":"10.1016\/j.jconrel.2026.114806_bb0240","author":"WHO"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114806_bib241","doi-asserted-by":"crossref","first-page":"e00007","DOI":"10.1128\/AAC.00007-19","article-title":"Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114806_bib242","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1021\/acs.molpharmaceut.0c00948","article-title":"Linking in vitro intrinsic dissolution rate and thermodynamic solubility with pharmacokinetic profiles of bedaquiline long-acting aqueous microsuspensions in rats","volume":"18","author":"Nguyen","year":"2021","journal-title":"Mol. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:04:21Z","timestamp":1781715861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926002087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0168365926002087"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114806","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of high-concentration long-acting injectable formulations of TBAJ-587 and TBAJ-876 as an extended treatment strategy against tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114806"}}